Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Talking Tough On DTC: Is Viagra Letter First Of Many?

Executive Summary

FDA will be forced to act if sponsors do not rein in direct-to-consumer advertising, Acting Commissioner Crawford declared during the Pharmaceutical Compliance Congress in Washington, D.C. Nov. 15

You may also be interested in...



Labeling Format Differentiation Minimized By Rule Implementation Timeline

FDA's implementation timeline for the physician labeling rule may mean that advent of the new labeling format will have limited impact on currently available competing products

Labeling Format Differentiation Minimized By Rule Implementation Timeline

FDA's implementation timeline for the physician labeling rule may mean that advent of the new labeling format will have limited impact on currently available competing products

Pfizer Exubera Launch May Demonstrate Impact Of Revised DTC Ad Policy

Launch of Pfizer/Sanofi-Aventis' inhaled insulin Exubera could demonstrate the impact of Pfizer's new direct-to-consumer advertising guidelines

Related Content

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel